Shipping and Receiving Research Peptides: Temperature Checks

The most commonly misunderstood step in the peptide workflow is the one nobody runs an experiment on: the journey from the supplier's freezer to yours. Shipping and receiving research peptides well is mostly a matter of understanding why the lyophilized state is forgiving, knowing which conditions it is not forgiving of, and building a short inspection and logging routine that catches problems before the material is dissolved and the evidence disappears.

Why lyophilized powder survives transit

Freeze-drying removes the water that most chemical degradation pathways need. Wang's review of lyophilization and solid protein pharmaceuticals lays out the underlying logic: the process is used precisely because the solid state offers acceptable shelf life where an aqueous formulation does not, though the freezing and drying steps themselves impose stresses, and solid-state stability is still finite [1].

The pathways that dominate in solution, deamidation of Asn and Gln, hydrolysis at Asp-X, disulfide scrambling, are all strongly slowed in a dry solid because molecular mobility is low [2]. This is why a short synthetic peptide typically tolerates several days at ambient temperature in transit while remaining well within specification, and why suppliers ship most lyophilized peptides without dry ice. The cost-benefit is straightforward: dry ice adds hazard-class paperwork and expense while addressing a risk that the dry state has already largely removed.

The exceptions are worth naming. Peptides supplied in solution, peptides with a known labile motif such as an Asp-Gly sequence, and material already reconstituted by the supplier should travel cold. So should anything where the supplier's own stability data indicate it.

What actually threatens a shipment

Three things, in rough order of importance:

Moisture. Residual and absorbed water is the main solid-state variable. A compromised stopper, a cracked vial or a broken seal admits humid air, and the resulting moisture both accelerates chemical degradation and can cause the cake to collapse or become sticky [1]. This is also why a vial should be brought to room temperature before opening: cold glass condenses atmospheric water inside the vial.

Oxygen. Methionine, cysteine and tryptophan oxidise, and oxidation proceeds in the solid state as well as in solution. A study of a model protein in lyophilized formulations demonstrated that peroxide contaminants present in an excipient accelerated oxidation in the solid state under air, and that preventing contact with air greatly limited peroxide formation in the first place [3]. Vials are typically sealed under vacuum or inert gas for this reason, and an unseated stopper defeats it.

Mechanical damage and light. Broken glass is obvious. Light exposure matters most for photolabile residues, which is why amber vials or opaque secondary packaging are used.

A fourth factor deserves a mention because it is invisible on arrival: surface loss. Peptides adsorb to glass and plastic to an extent that varies unpredictably between sequences and container types, and a study of eight radiolabelled endocrine peptides found substantial recovery differences between glass, untreated plastic and siliconised surfaces [4]. This is not usually a shipping problem for dry powder in its original vial, but it becomes one immediately if material is transferred into an unvalidated container on receipt. The practical rule is to leave the peptide where the supplier put it until you are ready to reconstitute.

Temperature, notably, is not top of this list for dry powder over a few days, although it becomes the dominant variable once the material is in your freezer for months. Long-term storage is covered in lyophilized peptide storage and stability.

A receiving routine that takes three minutes

1. Photograph the package as opened, before unpacking. If anything is wrong later, this is the only record that exists.
2. Check the outer packaging for crushing, puncture or water damage.
3. Check each vial: intact glass, seated and undamaged stopper, intact crimp seal, label legible and matching the packing list.
4. Inspect the cake. A white to off-white cake, thin film or loose powder is normal. Note the appearance, including a low-fill vial that appears nearly empty, which is expected for milligram quantities. A melted, sticky, discoloured or liquid appearance is not.
5. Check the vacuum, where the vial is vacuum-sealed, by the way the stopper sits. A stopper that has risen suggests loss of seal.
6. Match the lot number on the vial against the certificate of analysis. If they differ, stop and query it; a certificate for a different lot describes different material. See how to read a peptide certificate of analysis.
7. Equilibrate to room temperature in the sealed pouch before opening, then transfer promptly to the designated storage condition.
8. Log it in the inventory: compound, lot, quantity, date received, condition on arrival, storage location, certificate reference. Lot-level record-keeping is discussed in lot numbers and traceability in peptide research.

Reading the paperwork against the vial

The certificate should state, at minimum, sequence, molecular formula and mass, HPLC purity with the method, observed mass with the ionisation method, net peptide content or the basis on which content was determined, counterion, appearance and storage recommendation.

Cross-check three things immediately:

• Sequence against expected mass. Recompute the monoisotopic mass from the written sequence and compare it with the observed value. This catches transcription and amidation errors.
• Net peptide content. This is what determines the molarity of every stock you will make, not the vial's nominal mass.
• Counterion. Trifluoroacetate, acetate and hydrochloride salts behave differently in cell-based assays, so the salt form belongs in your notes from day one.

BPC-157 is a convenient example of a well-behaved shipment: a 15-residue sequence with no cysteine and no methionine, so the oxidation pathways that complicate transit for other peptides do not apply, and a certificate for it should be straightforward to reconcile against the vial. Per-lot data for catalogue peptides are published on our lab reports page.

After receiving: the first handling decision

The highest-risk moment for a peptide is not transit but the first reconstitution, because that is when the material enters solution and starts accumulating freeze-thaw and adsorption losses. Plan aliquoting before opening the vial rather than after, as discussed in freeze-thaw cycles and aliquoting peptide stocks. If the peptide will be used over months, weigh or reconstitute once and store single-use aliquots; repeated entry into one vial is the most common avoidable source of variability.

Key takeaways

• Lyophilized peptides tolerate ambient transit because low molecular mobility in the dry state suppresses the main degradation pathways.
• Moisture ingress and oxygen exposure, not brief warmth, are the real transit risks.
• Warm sealed vials to room temperature before opening to avoid condensing water inside.
• Inspect vial, seal and cake, and match the lot number on the vial to the certificate before use.
• Log condition on arrival and cross-check sequence, mass, net peptide content and counterion on day one.

This article summarizes published research for informational purposes. All Ascent Sciences products are for laboratory research use only and are not for human or animal consumption.

References

1. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60. PubMed
2. Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PubMed
3. Ha E, Wang W, Wang YJ. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci. 2002;91(10):2252-2264. PubMed
4. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. PubMed
5. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PubMed